Alaunos Therapeutics

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.


Founded in 2016, Alaunos Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for serious, life-threatening diseases. Our mission is to develop and bring to market new and innovative therapeutics that will revolutionize the treatment and management of these diseases.

Alaunos Therapeutics’ mission is to deliver life-saving treatments to patients and caregivers impacted by serious, life-threatening diseases.

Alaunos Therapeutics’ vision is to become a global leader in developing and delivering cutting-edge treatments and therapies that will revolutionize the treatment and management of serious, life-threatening diseases.

Key Team

Dr. Drew C. Deniger Ph.D. (VP of R&D)

Ms. Melinda Lackey (Sr. VP of Legal & Sec.)

Recognition and Awards
Alaunos Therapeutics has been recognized for its innovative therapies, such as the 2017 Global Challenge Award from the Bill and Melinda Gates Foundation and a Medal of Excellence from the American Academy of Sciences.

Alaunos Therapeutics
Leadership team

Mr. Kevin S. Boyle Sr. (CEO & Director)

Mr. Michael Wong (VP of Fin. & Principal Accounting Officer)

Mr. Abhishek Srivastava Ph.D. (VP of Technical Operations)

Products/ Services
Biotechnology, Genetics, Pharmaceutical, Therapeutics
New York, New York, United States
Company Registration
SEC CIK number: 0001107421
2M - 5M
Traded as
Social Media
Sat Feb 24 2024

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with

Copyright 2023 © businessabc powered by ztudium